Literature DB >> 2929445

When is QT prolongation antiarrhythmic and when is it proarrhythmic?

B N Singh.   

Abstract

Mesh：

Substances：

Year:  1989        PMID： 2929445     DOI： 10.1016/0002-9149(89)90059-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  13 in total

Review 1.  Risk-benefit assessment of amiodarone in the treatment of cardiac arrhythmias.

Authors:  P J Counihan; W J McKenna
Journal:  Drug Saf       Date:  1990 Jul-Aug       Impact factor: 5.606

Review 2.  Controlling cardiac arrhythmias: to delay conduction or to prolong refractoriness.

Authors:  B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 3.  Antipsychotic agents and QT changes.

Authors:  R Welch; P Chue
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

4.  Assessment of the effect of a single oral dose of telithromycin on sotalol-induced qt interval prolongation in healthy women.

Authors:  Jean-Louis Démolis; Soraya Strabach; Françoise Vacheron; Christian Funck-Brentano
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

Review 5.  When is drug therapy warranted to prevent sudden cardiac death?

Authors:  B N Singh
Journal:  Drugs       Date:  1991       Impact factor: 9.546

6.  The effects of L-thyroxine treatment on QT dispersion in primary hypothyroidism.

Authors:  Kyoung Hee Kweon; Byoung Hyun Park; Chung Gu Cho
Journal:  J Korean Med Sci       Date:  2007-02       Impact factor: 2.153

Review 7.  Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Authors:  A Fitton; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 8.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

Review 9.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 10.  Drug-induced torsade de pointes. Incidence, management and prevention.

Authors:  T S Faber; M Zehender; H Just
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.